Review anchor
Class 1 phosphodiesterase PDEB1
SINGLE PROTEIN · Trypanosoma brucei
As of 2026-09-13
Evidence Snapshot
Class 1 phosphodiesterase PDEB1
CHEMBL2010636
SINGLE PROTEIN
Trypanosoma brucei
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Class 1 phosphodiesterase PDEB1 as ChEMBL target CHEMBL2010636, mapped to UniProt Q8WQX9. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2010636
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q8WQX9
Phosphodiesterase
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Class 1 phosphodiesterase PDEB1 matters
Class 1 phosphodiesterase PDEB1 is reviewed as Phosphodiesterase (UniProt Q8WQX9); the current evidence base includes 1 approved drug, 270 compounds, and 21 assays, with lead potency reaching pChEMBL 8.5.
Protein context
Phosphodiesterase
Phosphodiesterase Sequence length is 930 aa.
Review this target as Class 1 phosphodiesterase PDEB1, mapped to UniProt Q8WQX9. ChEMBL maps the protein component as Phosphodiesterase. Sequence length is 930 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q8WQX9
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 270 compounds, and 21 assays for this target. The dominant activity type is KI. CHEMBL3765188 is the current potency anchor at pChEMBL 8.5.
Use CHEMBL3765188 as the tractability anchor when discussing potency (pChEMBL 8.5).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 8.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Class 1 phosphodiesterase PDEB1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q8WQX9, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
270
Total Compounds
21
Total Assays
1
Approved Drugs
IC50: 76.0, KI: 125.0, KD: 2.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3765188
|
8.5 | IC50 | — |
|
|
No preferred name
CHEMBL85005
|
8.4 | IC50 | — |
|
|
No preferred name
CHEMBL2326941
|
8.4 | IC50 | — |
|
|
No preferred name
CHEMBL2436771
|
8.4 | IC50 | — |
|
|
No preferred name
CHEMBL2326941
|
8.4 | Ki | — |
Source Header